Literature DB >> 8383741

Alpha adrenergic and mu-2 opioid receptors are involved in morphine-induced suppression of splenocyte natural killer activity.

D J Carr1, B M Gebhardt, D Paul.   

Abstract

The immunosuppressive effects following acute morphine administration have been mapped to opioid receptors in the central nervous system, specifically to the periaqueductal gray matter of the mesencephalon. The mesencephalon is associated with sympathetic neuronal processes, and the spleen is innervated with sympathetic neurons that are in direct apposition with lymphocytes in the periarteriolar lymphatic sheath. Accordingly, we investigated adrenergic involvement following morphine administration on natural killer (NK) activity by splenic lymphocytes. Acute morphine administration (25 mg/kg s.c.) suppresses (30-50%) NK activity by murine splenic immunocytes as measured in a 4-hr 51Cr-release assay. The suppression is blocked by phentolamine (4 mg/kg) and propranolol (10 mg/kg) in a dose-dependent fashion. However, phentolamine (2 mg/kg), but not propranolol (5 mg/kg), can also effectively antagonize morphine-induced immunosuppression. In addition, phentolamine (4 mg/kg) and prazocin (1 mg/kg), but not yohimbine (1 mg/kg), antagonizes morphine-elicited suppression of splenic NK activity. Selective opioid receptor antagonists were also utilized to determine the type or subtype of receptor activated following morphine administration. beta-Funaltrexamine (40 mg/kg) but not naloxonazine (35 mg/kg), naltrindole (20 mg/kg) or norbinaltorphimine (10 mg/kg) effectively blocks morphine-induced suppression of splenic NK activity. Collectively, morphine interacts with 1) mu-2 opioid receptors (most probably centrally) and 2) activates both alpha and beta adrenergic pathways.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383741

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene.

Authors:  C Gavériaux-Ruff; H W Matthes; J Peluso; B L Kieffer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 2.  Current research on opioid receptor function.

Authors:  Yuan Feng; Xiaozhou He; Yilin Yang; Dongman Chao; Lawrence H Lazarus; Ying Xia
Journal:  Curr Drug Targets       Date:  2012-02       Impact factor: 3.465

3.  Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test.

Authors:  M Makino; Y Kitano; C Komiyama; M Hirohashi; K Takasuna
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

4.  MOR1 expression in gastric cancer: a biomarker associated with poor outcome.

Authors:  Ya-sai Yao; Ru-yong Yao; Li-kun Zhuang; Wei-wei Qi; Jing Lv; Fei Zhou; Wen-sheng Qiu; Lu Yue
Journal:  Clin Transl Sci       Date:  2014-12-02       Impact factor: 4.689

Review 5.  Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections.

Authors:  Sabita Roy; Jana Ninkovic; Santanu Banerjee; Richard Gene Charboneau; Subhas Das; Raini Dutta; Varvara A Kirchner; Lisa Koodie; Jing Ma; Jingjing Meng; Roderick A Barke
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-26       Impact factor: 4.147

Review 6.  Modulation of immune cell function by α(1)-adrenergic receptor activation.

Authors:  Laurel A Grisanti; Dianne M Perez; James E Porter
Journal:  Curr Top Membr       Date:  2011       Impact factor: 3.049

Review 7.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

8.  Neuroimmune mechanisms of opioid-mediated conditioned immunomodulation.

Authors:  Timothy B Saurer; Stephanie G Ijames; Kelly A Carrigan; Donald T Lysle
Journal:  Brain Behav Immun       Date:  2007-08-03       Impact factor: 7.217

9.  Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts.

Authors:  Catherine C McGowan; David D Weinstein; Charles P Samenow; Samuel E Stinnette; Gema Barkanic; Peter F Rebeiro; Timothy R Sterling; Richard D Moore; Todd Hulgan
Journal:  PLoS One       Date:  2011-04-25       Impact factor: 3.240

10.  Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control.

Authors:  Daniel Kapitzke; Irina Vetter; Peter J Cabot
Journal:  Ther Clin Risk Manag       Date:  2005-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.